• Bipolar I and schizoaffective disorders are debilitating, long-term, recurrent conditions with significant personal, social, and societal costs. 1 • These patients are often excluded from randomised clinical trials and many previous observational studies of these patients have been of limited size, duration, and scope. 2 
• The Bipolar Comprehensive Outcomes Study (BCOS) is the first
Australian prospective observational study evaluating the actual care of participants with bipolar I and schizoaffective disorders, and is also the first study to measure health care costs in this population.
• BCOS aims to:
-Examine the effectiveness of mood stabilisers in the treatment of participants with bipolar I disorder (manic, mixed, or depressed episode) or schizoaffective disorder. -Assess economic, clinical, and functional outcomes associated with treatment in a "real-life" context.
BACKGROUND BACKGROUND

STUDY DESIGN
• • Study Entry comparisons were assessed using Fisher's Exact Test for categorical measures and ANOVA or the medians test for continuous measures.
• All longitudinal profiles were assessed using Mixed Model Repeated Measures (MMRM) adjusted for the following: -Study entry factors: Age, gender, diagnosis, length of stay in previous 3 months, hospitalised, overall CGI-BP-S, alcohol dependence past 12 months (from MINI), smoking status, partner status, employment status, visit and site. -Medications taken during 12 months observation: amount of time on Mood Stabilisers and/or Antidepressants and/or Antipsychotic and/or Benzodiazepines/Hypnotics.
• MMRM using random effect for time & intercept. Model statement includes visit & visit 2 . Covariance Structure used was Spatial Power.
• Interaction effects were assessed at the 0.1 level.
DATA ANALYSIS DATA ANALYSIS
• Predictors of baseline illness severity were assessed using logistic regression with the same factors as the longitudinal analysis, with the following changes:
-The factors SF-36 PCS & MCS, EQ-5D, partner status, current suicidality (past month), and income status were added. Visit and site were removed. -Medications taken in the past 3 months since study entry was used instead of during 12 months of study.
• A backwards elimination approach was adopted to reduce the models.
• Clinically significant predictors were kept in the models despite statistical significance.
Enrolment has been completed. We now present data after 12 months follow-up
DATA ANALYSIS CONT DATA ANALYSIS CONT … … DEMOGRAPHICS DEMOGRAPHICS
Characteristics Overall
Age ( • The most commonly prescribed treatment was atypical antipsychotics combined with mood stabilisers (12.6%).
• 
CLINICAL STATUS
• Overall improvement in clinical outcomes after 12 months (mean±SE): • CGI-BP-S total scores split by level of depression:
CGI-BP-S total scores split by level of mania: 
FUNCTIONAL STATUS
• 67% of patients 'Low' on EuroQoL -Normal Indicator (age/sex adjusted)
• EQ-5D utility scores split by level of depression: 
KEY FINDINGS
• Overall improvement in clinical and functional outcomes over 12 months
• Participants with clinical depression had poorer clinical and functional outcomes than asymptomatic participants. Severity of mania predicted fewer outcome differences.
• Participants with poor self-assessed mental health and quality of life were more likely to be clinically depressed at baseline.
• Participants with alcohol dependence and longer hospitalisation periods were more likely to be clinically manic at baseline.
• Few changes were observed in distribution of treatment by class or number of medications over 12 months.
Clinical outcomes improved overall after 12 Clinical outcomes improved overall after 12 months observation in the BCOS study, with months observation in the BCOS study, with depression severity associated with poorer depression severity associated with poorer outcomes. Emerging trends can be further outcomes. Emerging trends can be further explored at the 24 month study endpoint explored at the 24 month study endpoint.
CONCLUSION
